Patent · US Active

Compounds for targeting mutant huntingtin protein and uses thereof

US12083108B2 · kind B2 · utility

0Cited by
4References
17Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 24, 2022
Grant dateSep 10, 2024
Priority date
Expiry dateMay 24, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D487/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.